

The anatomy of Aseptic Transfer:


where sterility becomes fragile

In bio-pharma, where the drug product cannot withstand terminal sterilization, **the sterility of components depends entirely on controlling the most fragile steps of the journey.**

The landscape evolved beyond the standard 121°C sterilization process:

- More modalities (biologics, ATMP, high-value / low-volume)
- More formats (RTU nested, syringe, cartridge)
- More pressure (speed-to-clinic + supply resiliency)

Let's explore the 6 process steps where sterility must be actively protected:



Fedegar's approach: taking ownership of the most fragile process transitions

By designing cycles around air removal, condensate behavior, and steam penetration, we make implicit risks explicit and controllable, turning regulatory compliance into a repeatable and defendable process outcome.